Pyridazinedione-based heterobicyclic covalent linkers and methods and applications thereof
US-2024425465-A1 · Dec 26, 2024 · US
Heterocyclic nuclear hormone receptor modulators
US9150592B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9150592-B2 |
| Application number | US-201314135793-A |
| Country | US |
| Kind code | B2 |
| Filing date | Dec 20, 2013 |
| Priority date | Dec 21, 2012 |
| Publication date | Oct 6, 2015 |
| Grant date | Oct 6, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The invention provides a compound of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.
First claim
Opening claim text (preview).
What is claimed: 1. A compound represented by the following formula: or a pharmaceutically acceptable salt thereof, wherein: Ring 1 is heterocyclic or heteroaromatic; X is N, N(R 4′ ), C(R 4 ), or C(R 4 )(R 4 ); Y is N, N(R 4′ ), or C(R 4 ); Z is N(R 4′ ), C(R 4 )C(R 4 ) or C(R 4 ); A is N(R 3′ ) or C(R 3 )(R 3 ); G and J are independently S, C(R 1 )(R 2 ), or N(R 3…
Assignees
Inventors
Classifications
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9150592B2 cover?
- The invention provides a compound of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.
- Who is the assignee on this patent?
- Cusack Kevin P, Gordon Thomas D, Hoemann Michael Z, and 8 more
- What technology area does this patent fall under?
- Primary CPC classification C07D513/04. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Oct 06 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).